Trial Science/Data

  • Dec 12, 2016
  • GM6 down-regulates SOD1 and alters expression of 89 genes associated with ALS
  • The ALS Bioinformatics poster with the listing of 89 ALS associated genes modulated by GM6 is online now
  • View Details
  • Sep 16, 2016
  • GM6 Overview
  • Genervon looked for and discovered the master regulator of the human nervous system.
  • View Details
  • Sep 16, 2016
  • Summary of GM604
  • Genervon's innovative hypothesis, drug discovery, drug development and clinical trials results for the last 20 years are summarized here below.
  • View Details
  • Sep 22, 2015
  • GM604 Reduced TDP-43 to Achieve Homeostasis in Heterogeneous ALS Patients
  • Researchers and clinicians have long recognized that ALS is a heterogeneous neurodegenerative disease. That is why it is so difficult to find a cure to ALS since its discovery over 140 years ago. One of the major pathological features observed in post-mortem tissue from patients with ALS is cytoplasmic neuronal aggregations formed by TDP-43 DNA binding Protein.
  • View Details
  • Jun 29, 2015
  • ALS Compassionate Use Results
  • Results of a single compassionate patient trial (GALS-C) of GM604 were submitted to the FDA. The results obtained support the Homeostasis Theory and the reduction of TDP43 by GM604 significantly modulated the disease progression
  • View Details
  • Jun 29, 2015
  • Updated Phase 2A GALS001 and GLAS-C Trial Results
  • An update of Phase 2A GALS001 and GLAS-C Trial Results on TDP-43 and other biomarker data
  • View Details
  • Jun 29, 2015
  • 10 Statements about GM604
  • The GALS100 Phase 2A double blinded randomized placebo control clinical trials results revealed statistically significant beneficial impacts in the treated group compared to the placebo group
  • View Details
  • Jun 29, 2015
  • Safety and Efficacy Summary of GM604
  • Highlights of GM604 safety and efficacy in treating ALS patients where statistical significance or a strong trend were found achieved
  • View Details
  • April 13, 2015
  • GM604 in a Nutshell
  • The layman version of the advance and innovative science summary of GM604
  • View Details
  • March 30, 2015
  • The Innovative and Advanced Science of GM604
  • It is important for all parties involved to invest time to understand the innovative and advanced science behind the discovery and development of the endogenous embryonic/fetal stage regulator, GM604 which is responsible for the differentiation (formation), monitoring and correction of the human nervous system. Genervon does not think neurodegenerative diseases can be cured by single target drugs as evidenced by the uniform failure of all of the over 170 clinical ALS trials. Based on that conviction Genervon spent over 15 years to discovery and to develop the novel and innovative multiple targets master regulator peptide drugs to restore homeostasis of patients with nervous system (CNS/PNS) diseases and disorders.
  • View Details
  • Feb 16, 2015
  • Rationale for Accelerated Approval
  • An encouraging story of Genervon and GM604
  • View Details
  • Feb 16, 2015
  • Does GM6 reduce C9orf72?
  • GM604 reduced the expression of C9orf72 by 47% in 2 hours.
  • View Details
  • Feb 06, 2015
  • GALS-001 Data Integrity: 30 steps to ensure Quality Control
  • View Details
  • Feb 03, 2015
  • Clinical Trials with Small Sample Sizes
  • Letter from Paul J. Lupinacci, PhD, Director of Biostatistics, WCCT Global
  • View Details
  • Jan 31, 2015
  • Bowser's Letter on Biomarkers
  • Professor Bowser is the top biomarker expert in ALS. He tested and analysis all the samples collected by MGH and Columbia, including the compassionate use late-stage ALS patient who has been paraplegic/vent for 8 years.
  • View Details
  • Oct 19, 2014
  • ALS Phase 2a Trial Results
  • Genervon has completed the analysis of its Phase 2a double blinded, randomized, placebo controlled clinical trials of Amyotrophic Lateral Sclerosis
  • View Details
  • Dec 15, 2009
  • Phase 1 Human Trial Results and Potential Adverse Events
  • No laboratory abnormalities of potential clinical concern were reported in the study
  • View Details

 

 


 
Copyright © 2017 Genervon Biopharmaceuticals, LLC. All rights reserved. All other trademarks or trade names are the property of their respective holders.